Table 5.
Antibiotic use during study periods
| Baseline | Heterogeneous | Homogeneous | |
|---|---|---|---|
| n = 457 | n = 176 | n = 135 | |
| No. of patients receiving antibiotics | 306 (67%) | 107 (61%) | 97 (72%) |
| No. of DDD/1,000 patient days | (%Δ to baseline) | (%Δ to baseline) | |
| Amoxicillin–clavulanic acid | 326 | 131 (−60%)* | 31 (−91%)* |
| Ceftriaxone | 134 | 130 (−3%) | 55 (−59%)* |
| Ceftazidime | 21 | 29 (+38%) | 9 (−57%) |
| Piperacillin-tazobactam | 38 | 9 (−74%) | 10 (−74%) |
| Carbapenems | 52 | 60 (+15%) | 96 (+54%) |
| Other beta-lactam antibioticsa | 283 | 167 (−41%) | 354 (+25%) |
| Total beta-lactam antibiotics | 854 | 526 (−39%) | 555 (−35%) |
| Aminiglycosides | 159 | 142 (−11%) | 91 (−43%)* |
| Quinolones | 150 | 129 (−14%) | 514 (+243%)* |
DDD defined daily dosage
aAmoxicillin, flucloxacillin, piperacillin
* p < 0.05 as compared to baseline